Pasithea Therapeutics (KTTA) to Release Earnings on Monday

Pasithea Therapeutics (NASDAQ:KTTA) is projected to release its results before the market opens on Monday, March 23rd. Analysts expect Pasithea Therapeutics to post earnings of ($0.18) per share for the quarter.

Pasithea Therapeutics Stock Performance

Shares of KTTA stock opened at $0.80 on Friday. The stock has a fifty day simple moving average of $0.82 and a two-hundred day simple moving average of $0.85. Pasithea Therapeutics has a 52-week low of $0.28 and a 52-week high of $3.79. The firm has a market capitalization of $18.40 million, a PE ratio of -0.16 and a beta of 0.20.

Hedge Funds Weigh In On Pasithea Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC increased its stake in shares of Pasithea Therapeutics by 43.7% during the third quarter. Citadel Advisors LLC now owns 67,341 shares of the company’s stock worth $48,000 after purchasing an additional 20,483 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Pasithea Therapeutics by 113.9% in the 4th quarter. Geode Capital Management LLC now owns 54,495 shares of the company’s stock worth $70,000 after buying an additional 29,020 shares during the last quarter. Jane Street Group LLC increased its stake in Pasithea Therapeutics by 137.0% during the 4th quarter. Jane Street Group LLC now owns 59,372 shares of the company’s stock worth $77,000 after buying an additional 34,319 shares in the last quarter. Two Sigma Investments LP acquired a new position in shares of Pasithea Therapeutics during the third quarter valued at approximately $26,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Pasithea Therapeutics in the fourth quarter valued at approximately $375,000. 23.92% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. HC Wainwright started coverage on Pasithea Therapeutics in a research note on Monday, December 8th. They set a “buy” rating and a $3.00 price objective for the company. Wall Street Zen upgraded Pasithea Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, January 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Pasithea Therapeutics in a research note on Monday, December 29th. Finally, Zacks Research upgraded shares of Pasithea Therapeutics to a “hold” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $3.00.

Pasithea Therapeutics Company Profile

Pasithea Therapeutics, Inc (NASDAQ: KTTA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and eventual commercialization of engineered antibody therapeutics for immunological diseases. Leveraging a proprietary discovery engine that integrates advanced computational biology, high-throughput screening and structural analysis, the company aims to identify and generate novel therapeutic molecules that modulate key immune pathways.

The company’s pipeline consists of multiple preclinical and early clinical candidates targeting autoimmune and inflammatory disorders.